Literature DB >> 7905149

Epstein-Barr virus persistence and virus-associated tumours.

G Niedobitek1, L S Young.   

Abstract

The Epstein-Barr virus (EBV) has been implicated in the aetiology of many human lymphoid and epithelial malignancies. Although EBV is B lymphotropic in vitro, it has been hypothesised that oropharyngeal epithelium is important in primary EBV infection, replication, and persistence in vivo, and that infection of B lymphocytes is secondary. This hypothesis has been challenged by several recent studies. On the basis of current evidence, we propose that primary EBV infection and virus persistence are mediated through B lymphocytes, and that latent infection of epithelial cells is accidental and irrelevant to virus persistence, although important in the development of certain carcinomas. To what extent T cells are involved in EBV persistence remains uncertain. Clarification of the possible part played by EBV in the development of virus-associated tumours requires a better understanding of the mode of EBV persistence and the identification of the stage in the carcinogenic process at which EBV infection occurs.

Entities:  

Mesh:

Year:  1994        PMID: 7905149     DOI: 10.1016/s0140-6736(94)91167-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  28 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

2.  Oligo-monoclonal immunoglobulins frequently develop during concurrent cytomegalovirus (CMV) and Epstein-Barr virus (EBV) infections in patients after renal transplantation.

Authors:  E Drouet; C Chapuis-Cellier; S Bosshard; C Verniol; A Niveleau; J L Touraine; J L Garnier
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 3.  Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis.

Authors:  Javier S Burgos
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Tissue distribution of Epstein-Barr virus genotypes.

Authors:  H L Chen; M L Lung; K H Chan; B E Griffin; M H Ng
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Expression of bcl-2 and Epstein-Barr virus LMP1 in lymphocytic interstitial pneumonia.

Authors:  P M Kaan; R G Hegele; S Hayashi; J C Hogg
Journal:  Thorax       Date:  1997-01       Impact factor: 9.139

6.  CD21-Dependent infection of an epithelial cell line, 293, by Epstein-Barr virus.

Authors:  J D Fingeroth; M E Diamond; D R Sage; J Hayman; J L Yates
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

7.  ICAM-1, soluble-CD23, and interleukin-10 concentrations in serum in renal-transplant recipients with Epstein-Barr virus reactivation.

Authors:  M W Hornef; G Bein; D Wilhelm; L Fricke; H Kirchner
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

Review 8.  Historical background.

Authors:  M A Epstein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-04-29       Impact factor: 6.237

Review 9.  Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases.

Authors:  Silvia Montaner; Irina Kufareva; Ruben Abagyan; J Silvio Gutkind
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-10-22       Impact factor: 13.820

10.  Biomolecular markers in cancer of the tongue.

Authors:  Daris Ferrari; Carla Codecà; Jessica Fiore; Laura Moneghini; Silvano Bosari; Paolo Foa
Journal:  J Oncol       Date:  2009-08-19       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.